Latest Infectious Disease News

Page 5 of 5
Invion Limited reports no adverse events and early lesion reduction in its Phase I/II non-melanoma skin cancer trial, advancing to dose optimization.
Ada Torres
Ada Torres
29 May 2025
Noxopharm has secured ethics approval to commence the HERACLES trial, marking the first human study of its novel SOF-SKN™ drug aimed at chronic inflammatory diseases.
Ada Torres
Ada Torres
29 May 2025
Genetic Signatures Ltd reported a robust 71% jump in quarterly sales to $2.9 million, fueled by strong respiratory testing demand in Australia and key US commercial contracts. The company is advancing its automation and instrument customisation strategy to streamline molecular diagnostics offerings.
Ada Torres
Ada Torres
30 Apr 2025
Noxopharm Limited has successfully cleared key preclinical hurdles for its SOF-SKN™ lupus drug and expanded its Sofra™ platform collaborations, supported by fresh funding to propel upcoming clinical trials.
Ada Torres
Ada Torres
30 Apr 2025
Atomo Diagnostics reports a robust Q2 FY25 with $1.2 million revenue driven by HIV self-test sales and a significant $2.44 million government grant for syphilis test development. The company advances its market footprint in Australia and New Zealand while maintaining a strong cash position.
Ada Torres
Ada Torres
30 Jan 2025
Recce Pharmaceuticals has successfully dosed all patients in its Phase II trial of RECCE® 327 topical gel for acute bacterial skin infections, showing encouraging preliminary efficacy and safety data. The company is preparing for pivotal Phase III trials in Australia and Indonesia, targeting a significant global market opportunity.
Victor Sage
Victor Sage
21 Jan 2025
Immuron has submitted its Phase 2 clinical study report for Travelan® to the FDA, revealing statistically significant immunological and microbiome benefits. The company is preparing to engage the FDA for Phase 3 trial discussions while progressing a large field study with military personnel.
Ada Torres
Ada Torres
14 Jan 2025